
The FDA has approved rifaximin(Xifaxan), from Salix Pharmaceuticals,Inc., for treatment of traveler’sdiarrhea caused by noninvasive strains of Escherichia coli. Rifaximinis a nonsystemic, GI-selective, oralantibiotic; the recommended dosageis 200 mg tid for 3 days.
































































































































